論文・技術情報追加のお知らせ

1. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.

FAERSを用いたベダキリンの安全性調査

対象DB：FAERS

2. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.

FAERSを用いたルマテペロンの安全性調査

対象DB：FAERS

3. Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia.

ラインゾリドによる血小板減少の主要なリスク因子はランソプラゾールの併用

対象DB：FAERS

4. Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System.

COVID-19ワクチン接種後の更年期後出血はVAERSで稀

対象DB：FAERS,VAERS

5. Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report.

8歳未満の子供におけるテトラサイクリンの安全性をFAERSで調査

対象DB：FAERS

6. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.

経口セマグルチドの安全性に関するデータマイニング研究

対象DB：FAERS

7. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.

JAK阻害剤と心血管イベントの関連性

対象DB：CVAR,FAERS

8. Teprotumumab Related Hearing Loss: A Large-Scale Analysis and Review of Voluntarily Reported Patient Complaints to the Food and Drug Administration (FDA).

テプロツマブ使用と聴覚障害の関連性を調査

対象DB：FAERS

9. Safety assessment of clomiphene: a real-world pharmacovigilance analysis from the Food and Drug Administration adverse event reporting system.

クロミフェンの安全性に関する包括的な概要を提供

対象DB：FAERS

10. Neurological disorders following the use of tumor necrosis factor-alpha inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis.

FAERSを用いたTNFα阻害剤使用と神経学的有害事象の研究

対象DB：FAERS

11. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.

FAERSを用いて抗腫瘍ADCの心血管有害事象を分析

対象DB：FAERS

12. A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.

FAERSを用いてカプマチニブによる副作用のデータマイニングを行った。

対象DB：FAERS

13. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.

FAERSを使用して、フルベストラントに関連する重篤な有害事象を調査

対象DB：FAERS

14. An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database.

FAERSデータで抗てんかん薬の自殺や自傷行動の報告を分析

対象DB：FAERS

15. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.

PARP阻害剤の毒性をRCTとFAERSデータベースから評価

対象DB：FAERS

16. Peer Review for "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis".

GLP-1受容体作動薬と甲状腺障害の関連を検討

対象DB：FAERS

17. An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.

SEMのオフラベル使用に伴うリスクについて調査

対象DB：EudraVigilance

18. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.

T-DM1とT-DXdの副作用比較

対象DB：EudraVigilance

19. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.

SGLT2阻害剤の安全性についての検討

対象DB：EudraVigilance,VigiBase

20. Acetazolamide-induced pulmonary oedema: A disproportionality analysis from the EudraVigilance database.

アセタゾラミドと肺水腫の関連性を検証

対象DB：EudraVigilance,VigiBase

21. Surgical Risk in Elderly Patients with Meningiomas in Japan.

高齢者の脳膜腫手術におけるリスク要因を検討

対象DB：DPC

22. Safety of pyrazinamide in elderly patients with tuberculosis in Japan: A nationwide cohort study.

高齢者の結核治療において、ピラジナミド（PZA）の使用が安全であることが示唆

対象DB：DPC

23. Association between hospital case volume and maternal adverse events in patients with placental abruption: An analysis using a Japanese national inpatient database.

施設の出産件数と胎盤剥離患者の予後に明確な関連なし

対象DB：DPC

24. Changes in Treatment Conditions for Patients Receiving Hemodialysis at Nippon Medical School Hospital during the COVID-19 Pandemic.

COVID-19パンデミック後、透析患者の手術と入院期間が増加

対象DB：DPC

25. Survey on Actual Management of Osteoporosis with the Japanese Medical Data Vision Database in Elderly Patients Undergoing Spinal Fusion.

高齢者の脊椎融合手術における骨粗鬆症管理調査

対象DB：MDV

26. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.

日本のATTR-CM患者でのタファミジスの高い遵守率

対象DB：MDV

27. Predicting type 1 diabetes in children using electronic health records in primary care in the UK: development and validation of a machine-learning algorithm.

機械学習アルゴリズムによる1型糖尿病早期検出

対象DB：CPRD

28. Enhancing recruitment of individuals living with frailty, multimorbidity and cognitive impairment to Parkinson's research: experiences from the PRIME-UK cross-sectional study.

パーキンソン症候群患者の包括的な研究参加戦略

対象DB：CPRD

29. Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom.

自己免疫疾患は胃癌リスクを増加させる

対象DB：CPRD

30. First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study.

妊娠初期のASMs使用は流産リスク増加と関連せず

対象DB：CPRD

31. Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study.

GPPは異なる病態で医療利用が多い

対象DB：CPRD

32. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.

5ARI使用は前立腺癌リスクを低減

対象DB：CPRD

33. Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model.

OMOP CDMで標準的な1日薬用量計算法を開発

対象DB：CPRD

34. Using a general practice research database to assess the spatio-temporal COVID-19 risk.

IntegoデータはCOVID-19流行分析に有用

対象DB：GPRD

35. Antihypertensive Medications and Eczematous Dermatitis in Older Adults.

降圧薬は高齢者の湿疹リスクを増加

対象DB：THIN

36. Time- vs Step-Based Physical Activity Metrics for Health.

高齢女性の活動時間と歩数は、死亡率と心血管疾患に同等に関連

対象DB：DeSC